PTEN signaling pathways in glioblastoma

Cancer Biology and Therapy

Volumn 7, Issue 9, 2008, Pages 1321-1325

  Koul, Dimpy ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cell cycle; Nuclear PTEN and glioblastoma; P53; PI3K; PTEN

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

CANCER CELL CULTURE; CELL CYCLE; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; MUTATIONAL ANALYSIS; NONHUMAN; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH; UPREGULATION;

EID: 52149096024     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.7.9.6954     Document Type: Review

References (61)

1. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM, Bos JL. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-32.
2. Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC. mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 2005; 7:356-368.
3. Guha A, Feldkamp MM, Lau N, Boss G, Pawson A. Proliferation of human malignant astrocytomas is dependent on Ras activation. Oncogene 1997; 15:2755-2765.
4. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery 1999; 45:1442-1453.
5. Rajasekhar VK, Viale A, Socci ND, Wiedmann M, Hu X, Holland EC. Oncogenic Ras and Akt signaling contribute to glioblastoma formation by differential recruitment of existing mRNAs to polysomes. Mol Cell 2003; 12:889-901.
6. Holland EC. Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001; 2:120-129.
7. Reilly KM, Loisel DA, Bronson RT, McLaughlin ME, Jacks T. Nf1;Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000; 26:109-113.
8. Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J, Gutmann DH, Squire JA, Nagy A, Guha A. Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 2001; 61:3826-3836.
9. Shannon P, Sabha N, Lau N, Kamnasaran D, Gutmann DH, Guha A. Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol 2005;167:859-867.
10. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV.Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1995;15:356-62.
11. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997; 275:1943-7.
12. Teng DH, Hu R, Lin H, Davis T, Iliev D, Frye C, Swedlund B, Hansen KL, Vinson VL, Gumpper KL, Ellis L, El-Naggar A, Frazier M, Jasser S, Langford LA, Lee J, Mills GB, Pershouse MA, Pollack RE, Tornos C, Troncoso P, Yung WK, Fujii G, Berson A, Steck PA. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res 1997 ; 57 :5221-5.
13. Kolibaba, K. S., and Druker, B. J. Biochem. Biophys. Acta, Protein tyrosine kinases and cancer. 1331: F217-248, 1997.
14. Maehama T., Dixon J. E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem 1998; 273: 13375-13378.
15. Wymann, M. P., and Pirola, L. Structure and function of phophoinositide 3-kinases. Biochim. Biophys. Acta 1998; 1436: 127-150.
16. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akt. Genes Dev 1999; 13: 2905-2927.
17. Holland EC. Glioblastoma multiforme: the terminator. Proc. Natl. Acad. Sci. USA 2000; 97: 6242-6244.
18. Maher EA, Furnari FB, Bachoo RM, Rowitch DH, Louis DN, Cavenee WK, DePinho RA. Malignant glioma: genetics and biology of a grave matter. Genes Dev. 2001; 15:1311-1333.
19. Wechsler-Reya R, Scott MP. The developmental biology of brain tumors. Annu. Rev. Neurosci 2001; 24: 385-428.
20. Wu X, Senechal K, Neshat MS, Whang YE, Sawyers CL. PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc Natl Acad Sci U S A 1998; 95:15587-91.
21. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev 1999; 13: 2905-27.
22. Cheng JQ, Nicosia SV. AKT signal transduction pathway in oncogenesis Schwab D eds. . Encyclopedic reference of cancer 2001; 35-7.
23. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV, Cheng JQ. AKT1/PKB kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-7.
24. Cheng JQ, Altomare DA, Klein MA, Lee WC, Kruh GD, Lissy NA, Testa JR. Transforming activity and cell cycle-dependent expression of the AKT2 oncogene: evidence for a link between cell cycle regulation and oncogenesis. Oncogene 1997;14: 2793-801.
25. Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN. Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000; 25: 55-57.
26. Sonoda Y, Ozawa T, Aldape KD, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. Cancer Res 2001; 61: 6674-6678.
27. Furnari, FB, Huang HJ, and Cavenee WK. The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 1998; 58:5002-5008.
28. Li DM, and Sun H. PTEN/MMAC1/TEP1 suppresses the tumorigenicity and induces G1 cell cycle arrest in human glioblastoma cells. Proc. Natl. Acad. Sci 1998; 95:15406-15411.
29. Paramio JM, Navarro M, Segrelles S, Gomez-Casero E, and Jorcano JL. PTEN tumor suppressor is linked to the cell cycle control through the retinoblastoma protein. Oncogene 1999; 18:7462-7468.
30. Persad SA, Troussard A, McPhee TR,. Mulholland DJ, and Dedhar S. Tumor suppressor PTEN inhibits nuclear accumulation of β-catenin and T cell/lymphoid enhancer factor 1-mediated transcriptional activation. J. Cell Biol 2001; 153:1161-1174.
31. Weng LP, Brown JL, and Eng C. PTEN coordinates G1 arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum. Mol. Genet 2001; 10:599-604.
32. Sun H, Lesche R, Li DM, Liliental J, Zhang H, Gao J, Gavrilova N, Mueller B, Liu X, and Wu H. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol-3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci 1999; 96:6199-6204.
33. Zhu X, Kwon CH, Schlosshauer PW, Ellenson LH, and. Baker SJ. PTEN induces G1 cell cycle arrest and decreases cyclin D3 levels in endometrial carcinoma cells. Cancer Res 2001; 61:4569-4575.
34. Cheney IW, Neuteboom ST, Vaillancourt MT, Ramachandra M and Bookstein R. Adenovirus-mediated gene transfer of MMAC1/PTEN to glioblastoma cells inhibits S phase entry by the recruitment of p27Kip1 into cyclin E/CDK2 complexes. Cancer Res (1999); 59:2318-2323.
35. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000; 20:8969-82.
36. Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ, Lam EW and Burgering BM. Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol. Cell. Biol 2002; 22:2025-2036.
37. Mamillapalli R, Gavrilova N, Mihaylova VT, Tsvetkov LM, Wu H, Zhang H and Sun H. PTEN regulates the ubiquitin-dependent degradation of the CDK inhibitor p27(KIP1) through the ubiquitin E3 ligase SCF(SKP2). Curr. Biol 2001;11: 263-267.
38. Fujita N, Sato S, Katayama K and Tsuruo T. Akt-dependent phosphorylation of p27Kip1 promotes binding to 14-3-3 and cytoplasmic localization. J. Biol. Chem 2002; 277: 28706-13.
39. Zhou BP, Liao Y, Xia Y, Zou Y, Spohn B & Hung MC. HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation. Nat. Cell Biol 2001; 11: 973-982.
40. Mayo LD, Dixon JE, Durden DL, Tonks NK, and Donner DB. PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy. Biol. Chem 2002; 277: 5484-5489.
41. Ashcroft M and Vousden KH , Regulation of p53 stability. Oncogene 1999; 18:7637-7643.
42. Wu X, Bayle JH, Olson D, and Levine AJ. The p53-mdm-2 autoregulatory feedback loop. Genes Dev1993; 7: 1126-1132.
43. Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y, Benchimol S, and Mak TW. Regulation of PTEN transcription by p53. Mol. Cell 2001; 8: 317-325.
44. Lian Z and Di Cristofano A. Class reunion: PTEN joins the nuclear crew. Oncogene 2005; 24: 7394-7400.
45. Deleris P, Gayral S and Douillon MB. Nuclear Ptdlns(3,4,5)P3 signaling: An ongoing story. J. Cell. Biochem 2006; 98:469-485.
46. Lindsay Y, McCoull D, Davidson L , Leslie NR, Fairservice A, Gray A, Lucocq J and Downes CP. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J. Cell Sci 2006; 119: 5160-5168.
47. Li AG, Piluso LG, Cai X, Wei G, Sellers WR and Liu X. Mechanistic Insights into Maintenance of High p53 Acetylation by PTEN. Mol. Cell 2006; 23: 575-587.
48. Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R, Whale AD, Martinez-Diaz H, Rozengurt N, Cardiff RD, Liu X, Wu H. PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 2003; 3:117-30.
49. Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y. Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 2007; 128:157-70.
50. Okumura K, Zhao M, Depinho RA, Furnari FB, Cavenee WK. Cellular transformation by the MSP58 oncogene is inhibited by its physical interaction with the PTEN tumor suppressor. Proc Natl Acad Sci 2005; 102:2703-6.
51. Liu JL, Sheng X, Hortobagyi ZK, Mao Z, Gallick GE, Yung WK. Nuclear PTEN-mediated growth suppression is independent of Akt down-regulation. Mol Cell Biol 2005; 25:6211-24.
52. Metjian A, Roll RL, Ma AD, Abrams CS. Agonists cause nuclear translocation of phosphatidylinositol 3-kinase . A Gß-dependent pathway that requires the p110 amino terminus. J Biol Chem 1999; 274:27943-7.
53. Tanaka K, Horiguchi K, Yoshida T, et al. Evidence that a phosphatidylinositol 3,4,5-trisphosphate-binding protein can function in nucleus. J Biol Chem 1999; 274:3919-22
54. Ahn JY, Rong R, Liu X, Ye K. PIKE/nuclear PI 3-kinase signaling mediates the antiapoptotic actions of NGF in the nucleus. EMBO J 2004; 23:3995-4006.
55. Lindsay Y, McCoull D, Davidson L, Leslie NR, Fairservice A, Gray A, Lucocq J, Downes CP. Localization of agonist-sensitive PtdIns(3,4,5)P3 reveals a nuclear pool that is insensitive to PTEN expression. J Cell Sci 2006; 119:5160-8.
56. Chung JH, Eng C. Nuclear-cytoplasmic partitioning of phosphatase and tensin homologue deleted on chromosome 10 (PTEN) differentially regulates the cell cycle and apoptosis. Cancer Res 2005; 65:8096-100.
57. Gil A, Andrés-Pons A, Fernández E, Valiente M, Torres J, Cervera J, Pulido R. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Biol Cell 2006;17:4002-13.
58. Li AG, Piluso LG, Cai X, Wei G, Sellers WR, Liu X. Mechanistic insights into maintenance of high p53 acetylation by PTEN. Mol Cell 2006; 23:575-87.
59. Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ and Sahin AA. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117-127.
60. She QB, Solit DB, Ye Q, O'Reilly QE, Lobo J and Rosen N. The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 2005; 8: 287-297.
61. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S and E.Q. Dia et al., Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005; 353: 2012-2024.